ALNY - Alnylam Corp Revenue Dynamics YoY (Last Twelve Months)

Graphic logo of Alnylam Corp (ALNY)

Alnylam Pharmaceuticals (ALNY) seeks to solidify its leadership in RNA interference by expanding into the treatment of mass pathologies. The rolling annual sales growth rate reflects revenue dynamics, where the indicator value reaches 56.20. The implementation of robotic oligonucleotide synthesis is accelerating the development of new therapies. Financial stability is supported by licensing deals and joint gene therapy research with global behemoths.

ALNY Alnylam Pharmaceuticals, Inc.: Sales Growth YoY (Last Twelve Months) in the range 02/11/2024 - 11/18/2026

alnylam.com (ALNY) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Summary company analytics:ALNY (Alnylam Corp)
Mass-produced product of Alnylam Pharmaceuticals

This indicator reflects operational efficiency by smoothing quarterly volatility through the calculation of rolling year-over-year revenue growth to identify true market momentum. For Alnylam Pharmaceuticals (ALNY), this methodology enables the tracking of the transition from a narrow orphan drug niche to the mass cardiology market, as clearly demonstrated by the rolling year-over-year commercial revenue dynamics.

Competitors of Alnylam Pharmaceuticals (ALNY)